S. Chakravarty

发表

NMR Spin-Lattice Relaxation and EPR Linewidth in High Tc Materials

R. Orbach, S. Chakravarty, 1990 .

A Systematic Study of the Sar in Second Generation Bradykinin Antagonists Leads to the Design of the First High Affinity Cyclic Peptide Antagonists

S. Chakravarty, D. Kyle, B. Mavunkel, 1994 .

Synthesis and characterization of pseudopeptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one ring system.

E. Novotny, S. Chakravarty, D. Kyle, 1996, Journal of medicinal chemistry.

Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profiles.

Jie Hu, S. Chakravarty, Joon Jung, 2010, Bioorganic & medicinal chemistry letters.

A Selective p 38 Mitogen-Activated Protein Kinase Inhibitor Reverses Cartilage and Bone Destruction in Mice with Collagen-Induced Arthritis

H. Genant, Yebin Jiang, S. Medicherla, 2006 .

Selective inhibition of p38alpha MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury.

G. Schreiner, A. Protter, S. Chakravarty, 2006, American journal of physiology. Heart and circulatory physiology.

Antinociceptive action of a p38α MAPK inhibitor, SD-282, in a diabetic neuropathy model

S. Medicherla, A. Protter, D. Yeomans, 2004, Pain.

A p38α Selective Mitogen-Activated Protein Kinase Inhibitor Prevents Periodontal Bone Loss

N. D’Silva, J. Kreider, K. Kirkwood, 2007, Journal of Pharmacology and Experimental Therapeutics.

Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo

T. Hideshima, K. Anderson, G. Schreiner, 2006, Leukemia.

Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.

T. Hideshima, K. Anderson, G. Schreiner, 2006, Leukemia.

Role of TGF-β/ALK5 kinase in Monocrotaline-Induced Pulmonary Hypertension

A. Zaiman, R. Tuder, H. Champion, 2008 .

Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension.

P. Sehgal, A. Zaiman, R. Tuder, 2008, American journal of respiratory and critical care medicine.

Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors.

A. K. Agarwal, C. Higgs, S. Bernales, 2017, Bioorganic & medicinal chemistry letters.

MDV3100: Tritium labeling at high specific activity.

S. Chakravarty, C. N. Filer, C. Byon, 2016, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

p38α Mitogen-Activated Protein Kinase Inhibition Improves Cardiac Function and Reduces Myocardial Damage in Isoproterenol-Induced Acute Myocardial Injury in Rats

G. Schreiner, A. Protter, A. Kapoun, 2004, Journal of cardiovascular pharmacology.

Temozolomide analogs with improved brain/plasma ratios - Exploring the possibility of enhancing the therapeutic index of temozolomide.

Vikas Dixit, Emma McCullagh, D. T. Hung, 2016, Bioorganic & medicinal chemistry letters.

Role of the TGF- b /Alk5 Signaling Pathway in Monocrotaline-induced Pulmonary Hypertension

P. Sehgal, A. Zaiman, R. Tuder, 2008 .

Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.

S. Rennard, Ying Wang, F. Wen, 2006, Molecular Pharmacology.

A Selective p38α Mitogen-Activated Protein Kinase Inhibitor Reverses Cartilage and Bone Destruction in Mice with Collagen-Induced Arthritis

H. Genant, Yebin Jiang, S. Medicherla, 2006, Journal of Pharmacology and Experimental Therapeutics.

A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.

H. Genant, Yebin Jiang, S. Medicherla, 2006, The Journal of pharmacology and experimental therapeutics.

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.

P. Richardson, D. Chauhan, T. Hideshima, 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antioedematogenic and antinociceptive actions of NPC 18521, a novel bradykinin B2 receptor antagonist.

J. Calixto, S. Chakravarty, D. Kyle, 1996, European journal of pharmacology.

Oral anti-inflammatory action of NPC 18884, a novel bradykinin B2 receptor antagonist.

J. Calixto, S. Chakravarty, D. Kyle, 1998, European journal of pharmacology.

A combinatorial approach to the identification of dipeptide aldehyde inhibitors of beta-amyloid production.

P. Harden, J. Higaki, S. Chakravarty, 1999, Journal of medicinal chemistry.

p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells.

Hui Wang, A. Protter, A. Kapoun, 2004, Journal of molecular and cellular cardiology.

p38α-Selective Mitogen-Activated Protein Kinase Inhibitor SD-282 Reduces Inflammation in a Subchronic Model of Tobacco Smoke-Induced Airway Inflammation

S. Medicherla, A. Protter, A. Kapoun, 2008, Journal of Pharmacology and Experimental Therapeutics.

TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.

P. Richardson, D. Chauhan, T. Hideshima, 2004 .

Discovery of MDV6058 (PF-06952229), a Selective and Potent TGFβR1 Inhibitor: Design, Synthesis and Optimization.

S. Soni, S. Bernales, K. Mukherjee, 2022, Bioorganic & medicinal chemistry letters.

Oral antinociception and oedema inhibition produced by NPC 18884, a non-peptidic bradykinin B2 receptor antagonist

J. Calixto, S. Chakravarty, J. Ferreira, 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

Piperidine-based heterocyclic oxalyl amides as potent p38 alpha MAP kinase inhibitors.

S. Chakravarty, Joon Jung, Yong-jin Xu, 2010, Bioorganic & medicinal chemistry letters.

Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors.

O. Lenz, T. Verbinnen, S. Chakravarty, 2007, Bioorganic & medicinal chemistry letters.

Transforming Growth Factor-β Receptor Type 1 (TGFβRI) Kinase Activity but Not p38 Activation Is Required for TGFβRI-Induced Myofibroblast Differentiation and Profibrotic Gene Expression

S. Rennard, Ying Wang, F. Wen, 2006, Molecular Pharmacology.

Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.

M. Weller, W. Wick, A. Protter, 2007, Neuro-oncology.

Pharmacological Properties of SD-282 – An α-Isoform Selective Inhibitor for p38 MAP Kinase

S. Medicherla, A. Protter, A. Kapoun, 2008, Pharmacology.

A proposed model of bradykinin bound to the rat B2 receptor and its utility for drug design.

D J Kyle, T. Stormann, S. Chakravarty, 1994, Journal of medicinal chemistry.

Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment

P. Richardson, D. Chauhan, T. Hideshima, 2004, Clinical Cancer Research.

Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced pain

C. Svensson, T. Yaksh, Yebin Jiang, 2008, Pharmacology Biochemistry and Behavior.

Targeting Endogenous Transforming Growth Factor β Receptor Signaling in SMAD4-Deficient Human Pancreatic Carcinoma Cells Inhibits Their Invasive Phenotype 1

M. Reiss, R. Schwarz, L. Higgins, 2004, Cancer Research.

Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.

Devleena Shivakumar, J. Lindquist, D. T. Hung, 2016, Bioorganic & medicinal chemistry letters.

Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.

M. Kolb, J. Gauldie, A. Protter, 2005, American Journal of Respiratory and Critical Care Medicine.

Dual Inhibition of Bruton’s Tyrosine Kinase and Phosphoinositide-3-Kinase p110δ as a Therapeutic Approach to Treat Non-Hodgkin’s B Cell Malignancies

Emma McCullagh, D. T. Hung, S. Bernales, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Stable Expression of the Human Kinin B1 Receptor in Chinese Hamster Ovary Cells

D. Proud, J. Bathon, S. Chakravarty, 1997, The Journal of Biological Chemistry.

Chapter 18. Inhibitors of p38α MAP kinase

S. Chakravarty, 2002 .

p 38 α Selective MAP kinase inhibitor , SD-282 , reduces inflammation in a sub-chronic model of tobacco smoke-induced airway inflammation

S. Medicherla, A. Protter, A. Kapoun, 2007 .

Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue.

J. Lewicki, G. Schreiner, S. Chakravarty, 2003, Bioorganic & medicinal chemistry letters.

Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness

Alison Murphy, Lingyun Li, S. Medicherla, 2007, Molecular Pharmacology.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

S. Medicherla, A. Protter, B. Cullen, 2009 .

Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.

D. Severance, D. T. Hung, S. Bernales, 2017, Bioorganic & medicinal chemistry letters.

p38 MAPK inhibition reduces diabetes-induced impairment of wound healing

S. Medicherla, A. Protter, B. Cullen, 2009, Diabetes, metabolic syndrome and obesity : targets and therapy.

Induction of Aryl Hydrocarbon Receptor-Mediated Cancer Cell-Selective Apoptosis in Triple-Negative Breast Cancer Cells by a High-Affinity Benzimidazoisoquinoline.

Y. Zhang, C. Plaisier, S. Bernales, 2023, ACS pharmacology & translational science.

Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.

S. Rennard, Ying Wang, F. Wen, 2006, Molecular pharmacology.

induced myofibroblast differentiation and pro-fibrotic gene expression

S. Rennard, Ying Wang, F. Wen, 2006 .

Suppression of Ah Receptor (AhR) increases the aggressiveness of TNBC cells and 11-Cl-BBQ-activated AhR inhibits their growth.

S. Bernales, D. Finlay, S. Chakravarty, 2023, Biochemical pharmacology.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

S. Medicherla, A. Protter, B. Cullen, 2009 .

Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.

Devleena Shivakumar, J. Lindquist, S. Bernales, 2016, Bioorganic & medicinal chemistry letters.

Inhibition of the mitogen activated protein kinase, p38α, prevents proinflammatory cytokine induction by human adherent mononuclear leukocytes in response to lipid loading

A. Joly, G. Schreiner, S. Chakravarty, 2001 .

DMSOTT-5859-p38 MAPK inhibition reduces diabetes-induced impair

S. Medicherla, A. Protter, B. Cullen, 2009 .

Dual Inhibition of Bruton’s Tyrosine Kinase and Phosphoinositide-3-Kinase p110δ as a Therapeutic Approach to Treat Non-Hodgkin’s B Cell Malignancies

Emma McCullagh, S. Bernales, L. Delgado, 2017, The Journal of Pharmacology and Experimental Therapeutics.

JPET # 238022 1 Dual Inhibition of Bruton ’ s Tyrosine Kinase and Phosphoinositide-3-Kinase p 110 δ as a Therapeutic Approach to Treat Non-Hodgkin ’ s B cell Malignancies

Emma McCullagh, L. Delgado, R. Rai, 2017 .

p38α Mitogen-Activated Protein Kinase Inhibition Improves Cardiac Function and Reduces Myocardial Damage in Isoproterenol-Induced Acute Myocardial Injury in Rats

A. Protter, A. Kapoun, S. Chakravarty, 2004, Journal of cardiovascular pharmacology.